New cancer imaging technology shows promise

July 19, 2013, University of Rochester Medical Center

(Medical Xpress)—A new imaging technology that combines ultrasound and laser technologies has been shown to be highly effective in identifying prostate cancer. The system, which was developed by University of Rochester Medical Center (URMC) researchers, could also ultimately be deployed to detect and track breast, kidney, liver, skin and thyroid cancers.

The new medical – called multispectral photoacoustic imaging – was created by Vikram Dogra, M.D., a professor in URMC's Department of Imaging Sciences, in collaboration with Naval Rao, Ph.D. from the Rochester Institute of Technology's Center for Imaging Technology.

Physicians currently have a suite of tools at their disposal to test for prostate cancer. Monitoring PSA levels, digital rectal examinations, and transrectal ultrasound are all used as frontline screening tools. The current gold standard for a of an aggressive vs. slow growing prostate cancer is a . But even this method – which is invasive, uncomfortable, and carries a risk of side effects – has its limitations; cancers are only successfully detected 70 percent of the time.

Seeing the need for a noninvasive and effective imaging technology to detect , Dogra and his colleagues began to explore the use of a that combines ultrasound and .

The system uses nanosecond long bursts of light from a laser to bombard the . This heats the tissue and creates thermal waves that can be detected by ultrasound. These signals are then used to recreate an image of the target tissue and – because different wave lengths elicit different responses – observe variations in . To accomplish this, the researchers used an acoustic lens to focus the image, a method that is more cost effective than the alternative electronic focusing system.

The system enables researchers to track the level of lipids (fat), water, and forms of hemoglobin found in the blood, all of which respond to different wave lengths from the laser. Fluctuations in these compounds can indicate a tumor's status. Hemoglobin, the protein in red blood cells responsible for transporting oxygen, is of particular interest. Increases in the level of deoxyhemoglobin – the form hemoglobin without the bound oxygen – significantly raises the odds that the tissue is malignant.

"By observing increases and decreases in these things, particularly deoxyhemoglobin levels, we can tell if the tissue is malignant or benign," said Dogra.

Earlier this year, the researchers presented the findings of the first study using multispectral photoacoustic imaging to evaluate prostate cancer specimens at a meeting of the meeting of the American Roentgen Ray Society. The system was able to identify 25 or 26 healthy prostates, and 12 of 16 cancerous prostates, a 96 percent and 81 percent success rate.

Dogra and his team are now in the process of developing a prototype version of their scanner and hope to begin clinical evaluation of the device within two years. They believe that the system will ultimately be significantly less expensive – both in terms of equipment cost and cost per test – than biopsies and that the underlying technology could ultimately be applied to several other forms of cancer.

Explore further: Laser optics plus ultrasound imaging holds promise as a noninvasive test for prostate cancer

Related Stories

Laser optics plus ultrasound imaging holds promise as a noninvasive test for prostate cancer

April 18, 2013
Multispectral photoacoustic imaging, which combines laser optics and ultrasound imaging technologies, can reliably distinguish between benign and malignant prostate tissue, a new study indicates.

New imaging agent has an appetite for dangerous prostate tumors

December 8, 2011
Non-invasive imaging detects prostate cancer earlier than ever before, but can't accurately distinguish between malignant and benign disease. According to Lawson Health Research Institute's Drs. John Lewis and Len Luyt, a ...

Contrast-enhanced ultrasound better detects high-grade prostate cancers with fewer biopsies

September 27, 2012
Contrast-enhanced ultrasound was found to better detect high-grade prostate cancer than conventional methods, making it a more appropriate approach for screening clinically important cancers and monitoring low-risk ones with ...

GPS-like technology helps diagnose prostate tumors

May 3, 2013
The lead investigator of a way to obtain images of prostate tumors and accurately diagnose them said Thursday that the new technology is the medical equivalent of a global positioning system for the prostate gland.

Recommended for you

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.